Positive phase 2 asthma results for Array Biopharma
Colorado-based Array BioPharma has announced positive phase 2 clinical trial results of its asthma treatment ARRY-502, which is an oral CRTh2 antagonist.
ARRY-502 is being evaluated in trials of US patients with mild to moderate persistent allergic asthma. The treatment achieved the trial’s primary endpoint, which was significant improvement in pre-bronchodilator Forced Expiratory Volume in one second (FEV1), a measure of lung function. Dosed at 200mg twice daily, ARRY-502 was found to improve FEV1 by 3.9% versus placebo.
“There remains a significant need for more convenient, safe and effective therapies for patients with persistent allergic asthma. ARRY-502 is the first oral non-steroidal drug since Singulair® (montelukast) to demonstrate clinically meaningful activity in allergic asthma and represents a potential new oral therapy that may meet these needs.”
Sally Wenzel M.D., Professor of Medicine and Director of the Asthma Institute at the University of Pittsburgh and lead investigator of this trial.
Approximately 25 million people in the US have asthma causing significant morbidity and mortality. Worldwide, the estimate is between 235 – 300 million people.
“With many asthma patients poorly controlled on currently available therapies, a drug targeting a novel, non-overlapping mechanism may present an important new option for millions of patients. We are seeking an appropriate partner to develop ARRY-502 to its full potential.”
Ron Squarer, Chief Executive Officer of Array.
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.